Global haemostasis and point of care testing

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 81-88

  Dargaud, Y ^a   Sorensen, B ^b   Shima, M ^c   Hayward, C ^d   Srivastava, A ^e   Negrier, C ^a  

^a UNIVERSITÉ LYON 1   (France)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d MCMASTER UNIVERSITY   (Canada)

^e CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Aggregation; Bleeding disorders; Dense granule release; Platelet function

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; THROMBIN; TRANEXAMIC ACID;

ARTICLE; BLEEDING DISORDER; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD COMPONENT THERAPY; DEVICES; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; GENETIC HETEROGENEITY; HEMOPHILIA; HEMOSTASIS; HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN INTERACTION; SUBSTITUTION THERAPY; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; TREATMENT INDICATION;

BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; ENDPOINT DETERMINATION; HEMOSTASIS; HUMANS; POINT-OF-CARE SYSTEMS; THROMBELASTOGRAPHY; THROMBIN;

EID: 84862859441     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02855.x     Document Type: Article

References (61)

1. Beltra′n-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11(4): 326-34.
2. Nichols WC, Amano K, Cacheris PM, et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88(4): 1183-7.
3. Ninivaggi M, Dargaud Y, van Oerle R, De Laat B, Hemker HC, Lindhout T. Thrombin generation assay using FIXa as a trigger to quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost 2011; 9: 1549-55.
4. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
5. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
6. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
7. Trossaert M, Regnault V, Sigaud M, Boisseau P, Lecompte T, Fressinaud E. Mild hemophilia A with factor VIII assay discrepancy: potential utility of thrombin generation assays. J Thromb Haemost 2008; 6: 486-93.
8. Santagostino E, Mancuso ME, Tripodi A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.
9. Va′radi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
10. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 2008; 14(Suppl 4): 20-7.
11. Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia 2010; 16: 223-30.
12. Dargaud Y, Lienhart A, Meunier S, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-8.
13. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
14. Lewis SJ, Stefens E, Florou G, et al. Measurement of global haemostasis in severe haemophilia A following FVIII infusion. Br J Haematol 2007; 138: 775-82.
15. Dargaud Y, Negrier C. Individually tailored prophylaxis in patients with severe hemophilia. J Coagulation Disord 2010; 2: 11-7.
16. Rugeri L, Quelin F, Chatard B, De Mazancourt P, Negrier C, Daragud Y. Thrombin generation in patients with FXI deficiency and clinical bleeding risk. Haemophilia 2010; 16: 771-7.
17. Dargaud Y, Luddington R, Gray E, Negrier C, Lecompte T, Petros S, Hogwood J, Bordet JC, Regnault V, Siegemund A, Baglin T. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139: 303-9.
18. Dargaud Y, Luddington R, Gray E, Lecompte T, Siegemund T, Baglin T, Hogwood J, Regnault V, Siegemund A, Negrier C. Standardisation of thrombin generation test - which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125: 353-6.
19. Hartert H. Blutgerinnungsstudien mit der thrombelastographie, einem neuen untersuchungsverfahren. Klinische Wochenschrift 1948; 26: 577-83.
20. Calatzis A, et al. A comparison of the technical principle of the roTEG coagulation analyser and conventional thrombelastographic systems. Ann Haematol 1996; 72(Suppl. 1): P90 (abstract).
21. Hvas AM, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
22. Rea CJ, et al. Factor XIII combined with recombinant factor VIIa: a new means of treating severe haemophilia A. J Thromb Haemost, 2011; 9: 510-6.
23. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: 348-52.
24. Chitlur M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142: 250-6.
25. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
26. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41(Suppl 1): 140-4.
27. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-65.
28. Young G, et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
29. Sorensen B, Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor-clinical outcome and laboratory observations. Thromb Haemost 2010; 103: 1275-6.
30. Sorensen B. Future pharmacological strategies in management of Haemophilia. Thromb Res 2010; Oct; 126(4): 259-61. Epub 2010 Feb 12
31. Braun PJ, Givens TB, Stead AG et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78: 1079-87.
32. Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of haemophiliaA patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436-41.
33. Toh CH et al. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation. Intensive Care Med 2003; 29: 55-61.
34. Matsumoto T, Shima M, Takeyama M et al. The measurement of low levels of factor VIII or factor IX in haemophiliaA and haemophiliaB plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4: 377-84.
35. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14: 83-92.
36. Kasuda S, Tanaka I, Shima M et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004; 10: 341-6.
37. Matsumoto T, Nogami K, Ogiwara K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost 2012; 107: 288-301.
38. Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7: 676-84.
39. Pai M, Wang G, Moffat KA, et al. Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol 2011; 136: 350-8.
40. Castilloux JF, Moffat KA, Liu Y, Seecharan J, Pai M, Hayward CP. A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples? Thromb Haemost 2011; 106: 675-82.
41. Quiroga T, Goycoolea M, Matus V, et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol 2009; 147: 729-36.
42. Hayward CP, Moffat KA, Castilloux JF et al. Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thromb Haemost 2011; 106: 675-82.
43. Pai M, Hayward CP. Diagnostic assessment of platelet disorders: what are the challenges to standardization? Semin Thromb Hemost 2009; 35: 131-8.
44. Hayward CP, Moffat KA, Plumhoff EA, Van Cott E. Approaches to investigating common bleeding disorders: An evaluation of North American coagulation laboratory practices. Am J Hematol 2012; 87 Suppl 1: S45-50.
45. Mezzano D, Quiroga T, Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost 2009; 35: 242-54.
46. Christie D. J., Avari T., Carrington L. R., Cohen E., DeBiase B. A., Harrison P., Kickler T. S., Kottke-Marchant K., Ledford-Kraemer M., Rand M. L., Schmaier A. H., McCabe White M. Clinical and Laboratory Standards Institute (CLSI). Platelet function testing by aggregometry; approved guideline. CLSI document H58-A (ISBN 1-56238-683-2), available on-line. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2008. 28[31], 1-45.
47. Hayward CP, Moffat KA, Raby A, et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-63.
48. Harrison P, Mackie I, Mumford A, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44.
49. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-9.
50. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35: 158-67.
51. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
52. Hayward CP, Moffat KA, Pai M, et al. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost 2008; 100: 134-45.
53. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93: 549-53.
54. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007; 92: 694-7.
55. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-83.
56. Mani H, Luxembourg B, Klaffling C, Erbe M, Lindhoff-Last E. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005; 58: 747-50.
57. Favaloro EJ, Mohammed S. Platelet function testing: auditing local practice and broader implications. Clin Lab Sci 2010; 23: 21-31.
58. Callan MB, Shofer FS, Wojenski C, Giger U. Chrono-lume and magnesium potentiate aggregation of canine but not human platelets in citrated platelet-rich plasma. Thromb Haemost 1998; 80: 176-80.
59. Hayward CP. Diagnostic evaluation of platelet function disorders. Blood Rev 2011; 25: 169-73.
60. Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61: 950-4.
61. Duncan EM, Bonar R, Rodgers SE, Favaloro EJ, Marsden K. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. Int J Lab Hematol 2008; 31: 398-406.